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Simple Summary: Glioblastoma (GBM) is the most aggressive brain tumor and most resistant to
therapy. The identification of novel predictive biomarkers or targets to counteract chemoresistance,
requires a better understanding of the GBM primary response to therapy. The aim of our study was to
assess the molecular response of GBM to the standard of care chemotherapy by temozolomide (TMZ).
We established a comprehensive map of gene expression changes after treatment and discovered that
GBM cells elicit a coordinated gene expression program after chemotherapy that differs between
sensitive and resistant cells. We found that a novel class of genes expressed as long non-coding RNAs
(lncRNAs) is involved in gene regulatory circuits in GBM and could represent novel markers of GBM
patient prognosis. By shedding light on the involvement of the non-coding genome in GBM, our results
may provide new mechanistic insight on lncRNAs and their importance in chemoresistance.
Abstract: Resistance to chemotherapy by temozolomide (TMZ) is a major cause of glioblastoma
(GBM) recurrence. So far, attempts to characterize factors that contribute to TMZ sensitivity have
largely focused on protein-coding genes, and failed to provide effective therapeutic targets. Long
noncoding RNAs (lncRNAs) are essential regulators of epigenetic-driven cell diversification, yet,
their contribution to the transcriptional response to drugs is less understood. Here, we performed
RNA-seq and small RNA-seq to provide a comprehensive map of transcriptome regulation upon
TMZ in patient-derived GBM stem-like cells displaying different drug sensitivity. In a search for
regulatory mechanisms, we integrated thousands of molecular associations stored in public databases
to generate a background “RNA interactome”. Our systems-level analysis uncovered a coordinated
program of TMZ response reflected by regulatory circuits that involve transcription factors, mRNAs,
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miRNAs, and lncRNAs. We discovered 22 lncRNAs involved in regulatory loops and/or with
functional relevance in drug response and prognostic value in gliomas. Thus, the investigation of
TMZ-induced gene networks highlights novel RNA-based predictors of chemosensitivity in GBM.
The computational modeling used to identify regulatory circuits underlying drug response and
prioritizing gene candidates for functional validation is applicable to other datasets.
Keywords: glioblastoma; temozolomide; lncRNA; regulatory circuit; chemoresistance; transcriptome
1. Introduction
Since the introduction of temozolomide (TMZ) [1] in 2005 as standard chemotherapy against
glioblastoma (GBM) [2], no additional drug has been identified to effectively slow down GBM
progression. Unfortunately, however, median patient survival remains dismal and resistance to TMZ is
inevitable. The epigenetic regulation of the O-6-methylguanine-DNA methyltransferase (MGMT) gene
is the only known determinant of the clinical response to TMZ [3–6], eventually however, both MGMT
methylated and unmethylated GBM develop resistance to TMZ. Additional resistance mechanisms are
being investigated, including alternative DNA repair pathways, receptor tyrosine kinase or tumor
suppressor (TP53, PTEN) signaling [7,8].
As studies of the transcriptional changes induced by TMZ mainly assessed long-term changes
following the selection of resistant clones, the primary impact of TMZ on the GBM transcriptome
remains elusive [9]. Moreover, available gene expression studies have traditionally been performed
on classical adherent serum-dependent GBM cell lines [10,11], while it has been recognized that
patient-derived tumor cells grown as three-dimensional spheres (commonly called glioma stem cells,
GSCs) represent improved GBM models that display cellular and molecular gradients relevant for
drug response studies [12,13].
Advances in next-generation sequencing (NGS) have revealed the importance of long non-coding
RNAs (lncRNAs) as major components of the human transcriptome [14]. LncRNAs are pleiotropic
regulators of transcription, acting as transcriptional enhancers [15] or scaffolds for chromatin remodeling
complexes [16,17], while a subset of lncRNAs, known as competing endogenous RNAs (ceRNAs),
can sequester miRNAs and prevent the binding of miRNAs to their mRNA targets [18,19]. LncRNAs
are implicated in cancer [20,21], including GBM [22–24], yet few lncRNAs have been characterized
at the functional level. Although a large number of lncRNAs are retrieved from sequencing data,
the prioritization of lncRNAs for functional analysis remains a common challenge.
In this project, using sequencing of small and long RNAs, we established the transcriptomic
changes induced by TMZ in patient-derived GBM stem-like cells [25], differing in drug sensitivity.
We found that TMZ elicited different gene expression programs in sensitive versus resistant GBM cell
lines and that the extent of transcriptomic alterations correlated with sensitivity to TMZ. In addition
to mRNAs, TMZ induced a large number of regulatory RNAs, especially lncRNAs. We inferred
and analyzed transcriptional regulatory circuits generated from the integration of small RNA-seq
and RNA-seq datasets, which were further integrated with clinical and independent molecular data.
We thus uncovered coordinated programs of drug response in GBM, i.e., regulatory circuits that involve
transcription factors (TFs), mRNAs, miRNAs, and lncRNAs. Finally, we identified several lncRNAs
that bear functional relevance for drug response whilst representing independent prognostic markers
in GBM patients.
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2. Results
2.1. Differential DNA Damage Responses in GBM Stem-Like Cells Treated with TMZ
We analyzed the response to TMZ of three patient-derived GBM stem-like cultures (NCH601,
NCH421k, and NCH644, referred later as GSCs) [25,26] and of a human neural stem cell line (hNSC.100,
referred later as NSCs) used as non-neoplastic control. We found that NCH644 GSCs, expressing
the MGMT DNA repair enzyme, showed high resistance to TMZ (IC50 (half maximal inhibitory
concentration) = 2.2 × 108 nM vs. 2.7–3.7 × 105 nM for the MGMT negative NCH421k and NCH601)
(Figure S1a). Since TMZ is rapidly converted to the short-lived active compound MTIC, we hypothesized
that a brief TMZ exposure could activate DDR. Therefore, we monitored established DDR markers
using multi-color flow cytometry: phosphorylation of the histone variant H2AX on serine 139 (G-H2AX)
present at double strand DNA breaks and phosphorylation of Ataxia telangiectasia mutated (ATM)
on serine 1981 (P-ATM) (Figure 1a). The basal levels of G-H2AX were heterogeneous already prior
TMZ treatment (Figure 1b, dotted line discriminates low and high subpopulations). NCH421k showed
a high basal level (40% G-H2AX high, Figure 1b), whereas NCH601 and NCH644 were similar to
NSCs (6–16% G-H2AX high). TMZ induced DNA double-strand breaks (G-H2AX) after 6 h in three
cell lines and after 24 h treatment in all cells (Figure 1b and Figure S1b). DDR activation as measured
by P-ATM labeling was relatively homogeneous at baseline, with NCH644 showing the lowest basal
level (Figure 1b, black lines indicate median expression in control conditions for each cell type). Upon
TMZ treatment, NCH421k and NCH644 displayed P-ATM induction and accumulated in the S/G2/M
phases of the cell cycle (Figure 1b), while NCH601 and NSCs showed little to no induction of P-ATM.
In this experimental setting, we could not observe the presence of a sub-G1 peak after 24 h TMZ
treatment indicative of apoptotic cells (Figure 1b). As expected, BrdU+ proliferative cells exhibited
higher levels of G-H2AX and P-ATM (Figure S1c). Taken together, our experiments revealed different
cellular behavior upon TMZ (Figure 1c) from highly responsive (NSCs and NCH601: low basal level
and strong induction of G-H2AX, no induction of P-ATM), mildly responsive (NCH421k, high basal
level and mild induction of G-H2AX, low induction of P-ATM) to low responsive (NCH644, low basal
level and strong induction of G-H2AX, strong induction of P-ATM and S/G2/M accumulation). These
results are in line with previous literature demonstrating the role of ATM in G2-M cell cycle block
and protection from cell death, thereby leading to TMZ resistance [27]. These responses may reflect
GBM cell heterogeneity and demonstrate the drug impact at an early time point. As we observed a
differential DDR activation between the cell lines at 24 h after TMZ treatment, we therefore used these
experimental conditions to further assess the primary transcriptional response to TMZ and identify the
associated regulatory circuits (Figure 1c).
2.2. LncRNAs Are a Major Component of the Transcriptional Response to TMZ
To determine the immediate transcriptional response of GBM to TMZ, we carried out RNA
sequencing from cells treated for 24 h with TMZ or vehicle. From the same RNA samples, we performed
small RNA sequencing, to allow the direct comparison of small RNA, mRNA and lncRNA expression
levels, an essential experimental set-up for accurate data integration.
Principal component analysis (PCA) identified individual variations between the respective GBM
lines as the main determinant of transcriptome variability (Figure S2a). In both datasets, the variability
measured by PC2 distinguished NCH644 cells from the other three cell lines and TMZ had a limited
effect on variability. We compared the expression of different RNA biotypes with or without TMZ
treatment (Table S1) and defined differential gene expression using a false discovery rate (FDR) < 5%
and an absolute fold change > 2 for mRNAs and > 1.5 for miRNAs and lncRNAs. The volcano plots in
Figure 2a represent the differentially expressed genes (DEGs) for mRNAs, lncRNAs, and miRNAs.
In addition to the regulation of mRNAs, we observed that regulatory RNAs (miRNAs and lncRNAs)
represented a large component of the transcriptome response elicited by TMZ (Figure 2a).
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Figure 1. Glioblastoma (GBM) cells differentially activate DDR (DNA damage Response) in response 
to TMZ (temozolomide). (a) Gating strategy used for flow cytometry analysis. NCH644 GSCs 
(Glioblastoma stem-like cells) after 24 h TMZ treatment are shown as an example. (1) Cells were 
distinguished from debris using Forward Scatter (FSC) and Side Scatter (SSC). (2) Cell doublets and 
aggregates were gated out based on their properties displayed on the SSC area (SSC-A) versus height 
(SSC-H) dot plot. (3) Dead cells were recognized by their strong positivity for the dead cell 
discrimination marker. (4) Proliferating cells were distinguished as BRDU+ (Bromodeoxyuridine / 5-
bromo-2'-deoxyuridine) events. DAPI (4′,6-diamidino-2-phenylindole)staining shows cell cycle 
profile. (5) DNA damage was assessed by measuring the levels of ɣ-H2AX whereas P-ATM 
(phosphorylated Ataxia telangiectasia mutated) was used to measure the extent of DDR activation. 
The gating applied discriminates between P-ATM positive vs. negative cells, and ɣ-H2AX high vs. 
low cells. Percentage of cells in each quartile is presented. (b) Response to TMZ was analyzed in GSCs 
(NCH601, NCH421k, and NCH644). Neural stem cells (hNSC.100) were used as a non-neoplastic 
control. DNA damage (ɣ-H2AX), DNA repair (P-ATM), and cell cycle profiles (DAPI) after TMZ 
treatment (TMZ 6 h and TMZ 24 h) or DMSO as vehicle, are measured in the indicated cell lines. 
Isotype controls for antibody staining are shown for each cell (Neg). Dotted lines separate low and 
Figure 1. Glioblastoma (GBM) cells differentially activate DDR (DNA damage Response) in response
to TMZ (temoz lomide). (a) Gating strategy us d for flow cytometry analysis. NCH644 GSCs
(Glioblastoma stem-like cells) after 24 h TMZ treatment are shown as an example. (1) Cells were
distinguished from debris using Forward Scatter (FSC) and Side Scatter (SSC). (2) Cell doublets
and aggregates were gated out based on their properties displayed on the SSC area (SSC-A) versus
height (SSC-H) dot plot. (3) Dead cells were recognized by their strong positivity for the dead cell
discrimination marker. (4) Proliferating cells were distinguished as BRDU+ (Bromodeoxyuridine
/ 5-bromo-2’-deoxyuridine) events. DAPI (4′,6-diamidino-2-phenylindole)staining shows cell cycle
profile. (5) DNA damage was assessed by m asuring the levels of G-H2AX whereas P-ATM
(phosphorylated Ataxia telangiectasia mutated) was used to measure the extent of DDR activation.
The gating applied discriminates between P-ATM positive vs. negative cells, and G-H2AX high vs.
low cells. Percentage of cells in each quartile is pres nted. (b) Respons to TMZ s analyzed in
GSCs (NCH601, NCH421k, and NCH644). Neural stem cells (hNSC.100) were used as a non-neoplastic
control. DNA damage (G-H2AX), DNA repair (P-ATM), and cell cycle profiles (DAPI) after TMZ
treatment (TMZ 6 h and TMZ 24 h) or DMSO as vehicle, are measured in the indicated cell lines.
Isotype controls for antibody staining are shown for each cell (Neg). Dotted lines separate low and
high G-H2AX cells, or G0/G1 and S/G2/M cell cycle (DAPI graphs). Percentage of G-H2AX high cells
and cells in the S/G2/M cell cycle phases is presented. Black lines indicate median expression of P-ATM
in DMSO treated cells. (c) GBM stem-like cells of different chemoresistance to TMZ: Low (NCH601),
Intermediate (NCH421k), and High (NCH644), and neural stem cells (hNSC.100) were further used for
transcriptional profiling and systems level analysis.
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representing the TMZ-regulated RNA subclasses in three GSCs (NCH601, NCH421k, NCH644) and 
one control neural stem cell line (hNSC.100): mRNAs (left panel), microRNAs (middle panel), 
lncRNAs (right panel). Each differentially expressed gene is represented by a dot and cell lines are 
indicated by different colors. Cut-offs for differential expression: FDR < 0.05 and absolute log FC > 2 
for mRNAs, and FDR < 0.05 and absolute log FC > 1.5 for non-coding RNAs. Genes not satisfying 
these criteria are in black. For visualization purposes, the vertical axis has a limit of -log10 (FDR) = 20. 
(b) Venn diagrams showing the intersection of RNAs regulated by TMZ from the four cell lines. (c) 
Heat map representing the enrichment score of the top three pathways associated with mRNAs 
regulated by TMZ in each cell line.  
Figure 2. Genome-wide transcriptional changes induced by TMZ in GSCs. (a) Volcano plots re re enting
the TMZ-regulated RNA subclasses in three GSCs (NCH601, 421k, NCH644) and one control
neural stem cell line (hNSC.100): mR As (left panel), microRNAs (middle panel), lncRNAs (right
panel). Each differentially expressed gene is represented by a dot and cell lines are indicated by different
colors. Cut-offs for differential expression: FDR < 0.05 and absolute log FC > 2 for mRNAs, and
FDR < 0.05 and absolute log FC > 1.5 for non-coding RNAs. Genes not satisfying these criteria are in
black. For visualization purposes, the vertical axis has a limit of -log10 (FDR) = 20. (b) Venn diagrams
showing the intersection of RNAs regulated by TMZ from the four cell lines. (c) Heat map representing
the enrichment score of the top three pathways associated with mRNAs regulated by TMZ in each
cell line.
The extent of the transcriptional response of GBM cells to TMZ was very different in NCH644
in comparison with the other GSCs and NSCs (Figure 2b). NCH601 cells, the most sensitive GBM in
our selection, displayed the largest number of differentially expressed mRNAs (614), miRNAs (51),
and lncRNAs (206), whereas in NCH644, the most TMZ resistant cell line, only 25 mRNAs, 12 miRNAs,
and 1 lncRNA were significantly deregulated (Figure 2b and Table S2). By comparing the overlap of
DEGs we found that individual gene regulation was not conserved across GSCs except for a limited
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number of genes e.g., SOCS3, CSMD1, and SULF2 (Figure 2b). The same was true for miRNAs and
lncRNAs. Interestingly, miR-19a-3p was the only common miRNA deregulated in all four cultures
including NSCs, while miR-19b-3p regulation was observed in all cells except NCH644.
We then asked if there was a coordinated TMZ-regulation of coding genes leading to statistical
functional pathway enrichment [28]. Although there was limited overlap of differentially expressed
mRNAs between cell lines, we identified several commonly enriched pathways in cells with similar
response to TMZ (Figure 2c). For example, the p53 pathway was shared in sensitive cells (hNSC.100
and NCH601) whereas enrichment of Notch/Wnt signaling was present in the resistant NCH644. As all
GSCs are TP53 WT (Figure S2b–d), the absence of p53 pathway induction in NCH421k and NCH644
upon TMZ is not due to a mutation in p53. In hNSC.100 we detected a heterozygous mutation p.K132M
which is a described cancer missense mutation. The differential pathway enrichment in sensitive
versus resistant GSCs is in line with the known role of p53 in drug sensitivity and the involvement of
developmental pathways (Notch/Wnt) in chemoresistance [29,30].
2.3. TMZ-Regulated LncRNAs Are Prognostic Markers of Overall and Disease-Free Survival for
Glioma Patients
A previous analysis of lncRNA expression on exon arrays from The Cancer Genome Atlas
cohort (TCGA) revealed 133 lncRNAs as putative prognostic markers in GBM [31]. Four of our
364TMZ regulated lncRNAs were also found in this dataset: ENSG00000224272, ENSG00000233230,
ENSG00000233695 (or GAS6-AS1), and ENSG00000246263 (Figure 3a). Using the webtool GEPIA [32],
we calculated their prognostic capacity on glioma overall (Figure 3b) and disease-free survival
(Figure S3a), and confirmed the positive prognostic value for ENSG00000246263 and ENSG00000224272
but not for ENSG00000233230. On the other hand, a high expression of GAS6-AS1 was a negative
prognostic factor in gliomas, as previously observed in gastric cancer [33]. We next compared the
expression of these four lncRNAs in GBM, lower grade gliomas (LGG), and normal brain (GTEX).
The median expression of each lncRNA was not significantly different between LGG and GBM or
between brain tumors and normal brain, except for ENSG00000224272, which was more expressed
in LGG than normal brain (Figure 3c). We then searched if the lncRNA expression differed in GBM
subgroups of better prognosis, taking into account either the promoter methylation of MGMT (GBM
patients who benefit from TMZ) or GBMs harboring a DNA hypermethylation gene signature (CIMP
phenotype). Within the GBM cohort, we found that the expression of the four selected lncRNAs
was independent of MGMT status (Figure S3b) and the CIMP phenotype (Figure S3c). In summary,
we identified novel lncRNAs that are regulated by TMZ and display prognostic value in GBM,
suggesting a role in tumor progression and response to therapy.
2.4. Computational Inference of TMZ-Associated RNA Interactome
A common challenge in noncoding RNA research is to predict the biological significance of newly
identified molecules and select key genes for functional validation. As noncoding RNAs exert major
functions in transcriptional regulation, we sought to uncover regulatory networks underlying the GBM
response to TMZ. To this aim, we developed a pipeline based on available information on lncRNA and
mRNA associations with transcription factors (TFs) and miRNAs.
To build such a global gene regulatory network of mRNAs, ncRNAs (miRNAs and lncRNAs),
and TFs, we first retrieved molecular association data from several databases: ChipBase, StarBase,
and miRcode databases (Figure 4a) [34–36]. TF-mRNA and TF-lncRNA associations from ChipBase
were based on Chip-seq data of TF binding to promoters of mRNAs and lncRNAs. From Starbase,
we extracted miRNA-mRNA/lncRNA associations from HITS-CLIP and PAR-CLIP experiments.
Additional computationally predicted miRNA-lncRNA associations were added from miRcode. After
gene annotation using Refseq for mRNAs, miRBase release 20 for miRNAs, and Ensembl for lncRNAs,
the molecular associations described in Figure 4a were combined to obtain a global background network
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that we named the “RNA interactome”. This exhaustive network contains regulatory interactions
among 107 TFs, 1851 miRNAs, 10’970 lncRNAs, and 18′812 mRNAs (Table S3).
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Figure 3. TMZ-regulat d lncRNAs as novel independe t GBM progn sis markers. (a) Overlap between
the 360 TMZ-regulated lncRNAs and 133 lncRNAs proposed to correlate with GBM patient prognosis
in the TCGA cohort [31]. (b) Kaplan Meier overall survival curves for the four overlapping lncRNAs
in gliomas patients. The number of patients (n) analyzed for each group (high lncRNA expression
group in red, low lncRNA expression group in blue) is indicated on the graphs. For each group n ≥ 329.
Hazard ratios (H.R) and significance (log rank p-value) are indicated on the graphs. (c) Box plots
of selected lncRNA medi n expressi n in GBM (n = 163) and lower grad gliomas (LGG, n = 518)
(in red) compared to control brain tissue (grey, n = 207). Significant expression change is indicated by a
red asterisk.
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Figure 4. Systems approaches used for the generation of the RNA interactome and gene regulatory
networks induced by TMZ in GBM. (a) Overview of the analysis pipeline, (b) gene regulatory networks
representing the molecular associations between different RNA biotypes in different GSCs: mRNAs,
miRNAs, lncRNAs, and transcription facto s (TFs). Up- an downregulated RNAs are shown in red
and blue, respectively. Different node shapes distinguish RNA biotypes: TF: square, miRNA: triangle,
mRNA: circle, lncRNA: hexagon.
Next, we mapped our experimental dataset of TMZ-induced DEGs on the RNA interactome and
extracted specific networks. In these networks, mRNAs coding for transcription factors were labeled as
TFs. These analyses resulted in cell line-specific subnetworks composed of RNA-RNA and/or TF-RNA
interactions. Cell line subnetworks were visualized as circular layouts (Figure 4b) using cytoscape,
where each cluster represents the RNA biotype (TFs, mRNAs, lncRNAs, or miRNAs). Inside each
cluster, nodes represent individual genes, with the sense of TMZ-induced deregulation indicated by
a color code (increased expression in red; decreased expression in blue) (Figure 4b). We found that
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some TMZ-regulated molecules appeared to organize in network hubs of highly connected genes
(Table S4). Furthermore, transcriptional responses to TMZ involved a great number of TF-mRNAs
and TF-lncRNAs interactions. These interactions involved the following transcription factors: MYC,
TFAP2A, TCF12, HEY1 and EGR1, FOS and BCL3 (Table S4). Gene regulatory networks were largely
composed by ncRNA interactions (miRNAs-mRNAs or miRNAs-lncRNAs) regulated by a specific
subset of miRNAs. Several DEGs, as for example MYC and miR-19a-3p, showed opposite regulation
by TMZ in the sensitive NCH601 and resistant NCH644 cell lines. This may indicate that the specific
gene regulatory network contains key regulators of TMZ response.
We next analyzed the connectivity between the DEGs. We identified complex subnetworks in
NCH601 and NCH421k that displayed a large number of DEGs. In contrast, only a small subnetwork
was detected in NCH644, which displayed relatively few TMZ-associated DEGs, with some of its
components being also present in NCH601 networks. We then measured the connectivity of each node
(i.e., a gene) by calculating the in-degree (number of interactions that target a node) and out-degree of
each node (number of out-going edges from a node). Notably, miR-19a-3p and miR-19b-3p displayed
high out-degree values in almost all cells, suggesting a prominent regulatory role for these miRNAs in
TMZ treatment response.
In parallel, we searched for putative promoter activities that may explain the observed
transcriptional changes using ISMARA web tool [37]. The analysis of promoter motifs highlights TFs
with different activity in response to TMZ without changes in their expression levels. We analyzed
the top 10 transcription factor motifs sorted by activities (z-value) and identified common promoter
motifs as for example YBX1, NRF1, and SP1 (Figure S4). Whereas this observation indicates that
common transcriptional regulators can react in response to TMZ, it also suggests that they do so
in opposite direction in resistant and sensitive cells: if they are activated/unchanged in responsive
cells (NSC and NCH601), they tend to be repressed in resistant cells (NCH421k and NCH644).
In summary, our genome-wide view of the transcriptional response to TMZ discerned sensitive and
resistant behaviors.
Taken together, these data show that TMZ treatment impacts not only mRNA expression, but also
miRNA and lncRNA levels, which may constitute regulatory networks with other RNA biotypes and
TFs. Such regulatory networks, which were mostly observed in sensitive cell lines, may provide novel
insight into chemosensitivity of GBM cells.
2.5. TMZ-Induced Transcriptional Regulatory Motifs Contain LncRNAs
To identify critical components of the transcriptional regulation elicited by TMZ, we analyzed cell
line specific subnetworks at a higher systems level and extracted feed-forward loops (FFLs) involving
TFs, miRNAs, mRNAs, or lncRNAs (Figure 5a). Such loops represent three-component interaction
motifs consisting of miRNA-mediated loops, TF-mediated loops or mixed loops, i.e., those involving a
dual interaction between TFs and miRNAs (Figure 5a). Transcriptional motifs were only present in the
GBM cell lines, as no TF was regulated in NSC upon TMZ. Although the NCH644 network included
a limited number of TMZ-regulated transcripts, we found two TF-mediated motifs with mRNAs
involving MYC and miR-19a-3p. Conversely, in the TMZ sensitive cell line NCH601, we identified 308
miRNA-mediated loops, 559 TF-mediated loops, and 136 mixed loops regulated by TMZ (see Table S5
and Figure S5a). Strikingly, miR-19a-3p associated motifs were present in all GBM cell lines, although
these associations involved different TFs, mRNAs, or lncRNAs depending on the cell line (Table S5).
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Figure 5. Identification of TMZ-associated transcriptional regulatory motifs involving lncRNAs.
(a) Graphical representation of the motif structures where mRNAs or lncRNAs are the targets regulated
by miRNA (miR) and TF associations. (b) Hive plot representing TMZ-regulated FFLs containing
lncRNAs from NCH601. Axes indicate different RNA families, with each dot corresponding to a gene
(TF, miRNA, or lncRNA) involved in lncRNA-containing loops. Molecular interactions are represented
by a color code line (stimulatory interactions in red, inhibitory interactions in blue). (c) Heatmap
showing enriched pathway for the indicated lncRNAs.
We focused on the composition of motifs involving lncRNAs, as such motifs were only present in
the most sensitive GSCs (NCH601). The 22 lncRNAs formed 104 loops by interaction with a limited
number of regulators (five TFs and six miRNAs, Figure 4b), as visualized by the hive plot in Figure 5b.
Notably, a small number of key regulators such as miR-19a/b, MYC, EGR1, and HEY1 were consistently
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present in most of the lncRNA-containing loops. To verify the non-coding identity of these 22 lncRNAs,
we retrieved their sequences [38], calculated their coding potential probabilities [39], and compared
them with those obtained from reference sets of known lncRNAs and mRNAs [40]. The lncRNAs
involved in TMZ-associated regulatory loops had a low coding probability, similar to other known
lncRNAs, suggesting that these lncRNAs are indeed noncoding (Figure S5b).
Among the 22 lncRNAs involved in loops, eight were expressed in all RNA-seq samples.
By calculating the expression correlation coefficient between lncRNAs and mRNAs (Table S6) and
pathway enrichment analysis using Webgestalt, we were able to associate these eight lncRNAs with
putative biological functions. Analysis of the top 10 pathways identified for each lncRNA based on
their statistical significance revealed that several pathways were shared (Figure 5c). Thus, five lncRNAs
were associated with cell cycle regulation and DDR and six lncRNAs with EGFR signaling and/or
developmental function (Figure 5c). As these functions were also enriched at the mRNA level
(Figure 2c), our data collectively strengthen the notion that the motif-specific lncRNAs identified by
our analysis are involved in biological functions relevant to drug response.
2.6. LncRNAs in TMZ Regulatory Loops May Function as CeRNAs
A subset of lncRNAs signal through binding of miRNAs, thereby acting as competing endogenous
RNAs (ceRNAs) with mRNAs. We investigated the TMZ associated gene regulatory networks
and selected mRNA-miRNA and miRNA-lncRNA pairs for the seven miRNAs involved in TMZ
regulatory loops (Figure 5b): let7e-5p, miR-124-3p, miR-19a-3p, miR-19b-3p, miR-34a-5p, miR34c-5p,
and miR-551b-3p. Interestingly, we found that except for miR-551b-3p (Figure S6), all miRNAs
investigated shared molecular interactions with mRNAs and lncRNAs (Figure 6 and Figure S6). Taken
together, these results suggest that these lncRNAs may act as sponges for miRNAs to fine tune the
expression of mRNAs regulated by TMZ.
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3. Discussion
The transcriptional response to chemotherapeutic drugs has so far been mostly analyzed at
the level of mRNAs, yet, a wealth of information is present in non-coding RNAs, making up more
than 90% of the human genome [41]. Here, we report that GSCs elicit a heterogeneous cellular and
transcriptional response to acute TMZ exposure. Although TMZ induced DNA damage in all cells,
DDR activation was only observed in the TMZ-resistant MGMT positive GSC. Yet, this strong DDR
activation was not associated with a major deregulation of the transcriptome in the resistant GSC,
which is in line with our recent study where TMZ did not induce phenotypic changes in this cell
line [42]. At present we cannot evaluate if and to what extent this is linked to MGMT expression in
this cell line. In our experimental conditions, we showed that TMZ induces cell cycle block in some
GSCs and we did not detect TMZ induction of apoptosis (subG1 peak) in GSCs, which is in line with
previous report [43,44]. As other studies have evidenced apoptosis induction by TMZ in GBM cells,
or more recently ferroptosis [6,45–47], it would be interesting to assess if the transcriptional changes
and regulatory circuits identified here are involved in TMZ mediated apoptosis.
Our study provides a comprehensive overview of the RNA regulatory circuits induced by TMZ
and lays the basis for exploring non-coding RNA function in GBM tumorigenesis and chemosensitivity.
The analysis of regulatory network identified key TF-miRs molecular interactions, as the crosstalk
between mir-19 and MYC [48]. Mir-19, a key oncogenic miRNA involved in glioma proliferation,
invasion, and progression [49–51], appears to be a central regulator of the transcriptional response to
TMZ. The upregulation of mir-19 in the resistant GSCs could participate in chemoresistance. Of note,
it was reported that mir-19 targeting decreased the expression of MYC and delayed GBM tumor
growth [52]. The systems-level characterization of lncRNAs and their inclusion in human-curated
databases are still at an early stage. A study investigating a ceRNA network, which was built with
co-expression measurements from paired genes (mRNAs and lncRNAs), proposed lncRNAs with
potential clinical relevance in GBM [53]. The present approach expands on a network generation and
analysis strategy that we previously reported in the context of miRNAs and GBM [54]. This strategy
resulted in a comprehensive integration of datasets and regulatory associations, which is required
to provide systems-level insights into specific cell models and treatment responses. An important
challenge for such a strategy is the lack of tools for full integration of the different modeling and
analysis steps. Another obstacle is the limitation imposed by the relatively poor consistency of ncRNA
annotations between databases [55]. The reannotation of existing patient datasets with lncRNA
expression [31] and sequencing of total RNAs could enhance the phenotypic studies of lncRNAs and
the predictive potential of network-based discovery strategies. Nevertheless, the strategy presented
here can be applied to multiple fields of cancer research investigating transcriptional programs
(treatment resistance, cell invasion, immuno-oncology), whilst also contributing to the development of
appropriate methodologies and analytical tools. In this regard, it is notable that the methodology we
implemented to prioritize lncRNA candidates for functional validation resulted in the identification of
a subset of lncRNAs with a putative role in DDR or developmental pathways. Among these novel
lncRNAs, the lncRNAs TP53TG1 and ENSG000246263, were recently uncovered in a study using a
machine-learning method to stratify cancer-related lncRNAs [56]. Furthermore, the documented roles
of TP53TG1 in glioma cell proliferation [57] and response to chemotherapy in lung cancer [58] provide
experimental support for our in silico prediction of a role for TP53TG1 in the response of GBM cells
to TMZ.
Our work has revealed that a large number of lncRNAs are differentially regulated by TMZ in
chemo-sensitive and resistant GSCs, as well as in non-malignant NSCs, and identified key lncRNAs that
may be linked to the regulation of DDR, apoptosis, and EGFR signaling in GBM, as part of co-expression
networks with mRNAs and other small RNAs. Although several DNA repair mechanisms are involved
in the repair of TMZ-induced lesions, TMZ resistance in the clinic has so far been associated mainly
with the activity of MGMT and the selection of resistant clones that account for tumor recurrence [8].
To date, albeit recent reports involve lncRNAs as regulators of drug sensitivity [59–61] and of GBM
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pathogenesis [22,23], a genome-wide analysis of lncRNAs in the regulation of drug response in GBM
has not been done. We expect that functional analyses of TMZ-associated lncRNAs will provide
valuable insight into the mechanisms that govern drug response in GBM. Given the importance of
lncRNAs in cellular lineage and as transcriptional enhancers, it is highly possible that some of the
lncRNAs identified in this study operate through epigenetic mechanisms that drive selection of resistant
cells, independently of MGMT. In this respect, we identify four lncRNAs with prognostic value in
glioma patients that are involved in the transcriptional response to TMZ, independent of MGMT status.
Although lncRNAs are generally expressed at low levels, it would be of interest to verify their prognostic
value by RNA in situ hybridization on glioma tissue. Additionally, as lncRNAs play important roles in
DNA damage signaling and chemoresistance, these molecules could have a functional role in TMZ
response independently of MGMT as recently shown for the lncRNA TP73-AS1 [62]. If confirmed,
targeting these molecules could be used to counteract chemoresistance in GBM.
4. Material and Methods
4.1. Cell Lines, Treatments, and Cytotoxicity Assay
The glioblastoma stem-like cell cultures NCH421k, NCH601 and NCH644 were generated in the
lab of Dr Christel Herold-Mende (Department of Neurosurgery, University of Heidelberg) [63]
and characterized previously [25]. Human fetal neural stem cells hNSC.100 were described
previously [64].All cell lines were grown as 3D neurospheres in serum-free medium. NCH421k and
NCH601 were cultured as non-adherent spheres in DMEM-F12 medium (Lonza, Basel. Switzerland)
containing 1xBIT100 (Provitro, Berlin, Germany), 2mM L-Glutamine, 30U/ml Pen-Step, 1U/ml Heparin
(Sigma), 20ng/ml bFGF (Miltenyi, Bergisch Gladbach, Germany 130-093-841) and 20ng/ml EGF
(Provitro, Berlin, Germany 1325950500). NCH644 and hNSC.100 grew as non-adherent spheres in
Neurobasal®base medium (ThermoFischer Scientific, Waltham, Massachusetts, USA) supplemented
with 1xB-27, 2mM L-Glutamine, 30U/ml Pen-Step, 1U/ml Heparin (Sigma), 20ng/ml bFGF and 20ng/ml
EGF. Temozolomide (TMZ, Sigma Aldrich, Overijse, Belgium, 76899) sensitivity was measured by
WST-1 assay (Roche, Basel, Switzerland, 5015944001) developed with Fluorostar Optima system. IC50
was determined using Graphpad Prism. Cell biomass was determined 72 h after TMZ treatment. Cells
were treated with 500 µM TMZ for 6 or 24 h for flow cytometry, and 24 h for RNA-seq experiments.
4.2. Multi-Color Flow Cytometry
TMZ or vehicle were added 24 or 6 h prior to analysis. For proliferation assay, BRDU
(Bromodeoxyuridine / 5-bromo-2’-deoxyuridine) incorporation was performed for 6 h before
the end of the experiment. Prior to fixation, cells were dissociated and incubated with the
IR-LIVE/DEAD®Fixable Dead Cell Stain (ThermoFisher scientific; Waltham, MA, USA, 1 µg/mL).
Cells were fixed, permeabilized and stained with the BD PharmingenTM BrdU Flow Kit (BD
Bioscience, San Jose, CA, USA) according to the manufacturer’s instructions. The following
conjugated antibodies were used: anti H2AX-Phospho Ser139-Alexa Fluor 647 (BD Biosciences,
560447), anti-ATM-PhosphoSer1981-PE (Millipore, Burlington, MA, USA, FCMAB110P), Alexa
Fluor®647 Mouse IgG1 κ Isotype Control (BD Bioscience, 565571), Mouse IgG1 Negative Control,
clone Ci4, PE conjugate (Millipore, MABC002H).DNA was counterstained with DAPI (1 ug/mL) and
anti–BrDU-PerCP-Cy5.5 (BD, 560809 kit). Data were acquired on a FACS AriaTM SORP cytometer (BD
Biosciences) and analyzed with Diva (BD Biosciences) and FlowJo software version v10.5.3.
4.3. RNA and Small RNA-Sequencing
Total RNA was extracted with Trizol and quantified using Nanodrop. Three biological replicates
were used per experimental condition. RNA quality was checked using a bioanalyzer (Agilent,
Santa Clara, CA, USA). Total RNAs were depleted from Ribosomal RNAs using RiboMinus™ technology.
RNA-seq libraries were prepared according to the Illumina standard protocol using TruSeq Stranded
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RNA Kits. Small RNA-Seq libraries were generated from total RNA using TruSeq Small RNA Library
Prep Kit. Single stranded sequencing reads were performed on HiSeq2500 instrument (Illumina,
San Diego, CA, United States). Base calling was performed with CASAVA 1.8.2 pipeline (Illumina).
Fastq data and processed counts of RNA-seq (24 samples in total) and small RNA-seq (24 samples in
total) are available through Gene Expression Omnibus (GSE98128).
4.4. Systems Approaches
The associations of TFs with genes, miRNAs, or lncRNAs were obtained from ChipBase [36].
Associations between miRNAs and genes were obtained from StarBase [35]. As the number
miRNAs-lncRNAs associations in StarBase was small, we also integrated the miRcode dabase [34].
As a result, the background regulatory network consisted of 1,145,815 regulations, including 107 TFs,
1851 mature miRNAs, 10,970 lncRNAs, and 18,812 genes. Detailed information is shown in Figure 4B.
Next, we mapped the DEGs (Differentially Expressed) genes, miRNAs, and lncRNAs of each cell
line into the background network separately. We constructed the cell line-specific subnetworks by
extracting the edges (observed expression correlation) between the DE nodes. We focused on three
types of 3-node FFLs containing lncRNAs or mRNAs, and which included a TF, a miRNA, and a target
lncRNAs or mRNAs (Figure 5a and Figure S5, respectively). In the first type, a TF regulates miRNA
and lncRNA, and a miRNA regulates lncRNA. We termed it TF-mediated FFL. In the second type,
miRNA-mediated FFL, a miRNA regulates TF and lncRNA, and a TF regulates lncRNA. In the third
type, a miRNA and a TF are mutually regulated, and both regulate a lncRNA. We extracted all FFLs
from the cell line-specific subnetworks using R-language scripts.
4.5. TCGA Data Analysis
Prediction of lncRNAs as potential prognostic markers were reported in [31], analyzed using
GEPIA, and GETX data were used for normal tissue expression. The MGMT promoter methylation
status was from [65]. Cohort was divided in two groups based on expression median for each lncRNA.
Group expression was represented using Graph Pad Prism or extracted from GEPIA.
5. Conclusions
In conclusion, this study provided a comprehensive map of transcriptome regulation upon TMZ
in GSCs displaying different drug sensitivity. The transcriptional response to TMZ is a coordinated
program of coding and non-coding RNAs, orchestrated by regulatory loops, some of them being
oppositely modulated in sensitive and resistant GBM cells. Importantly, we uncovered a subset of
largely unknown lncRNAs potentially involved in essential pathways of tumorigenesis and drug
resistance. Several TMZ regulated lncRNAs display prognostic value in GBM patients. This data
resource, the systems approaches, and novel RNA targets identified in this study open the way for
understanding lncRNA function in GBM.
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